Price Alert

Evotec SE (EVO)

NASDAQ: EVO · Real-Time Price · USD

3.81

0.00 (0.00%)

At close: Aug 14, 2025, 3:59 PM

3.70

-2.76%

Pre-market: Aug 15, 2025, 09:08 AM EDT

0.00% (1D)

Bid	3.68
Market Cap	1.35B
Revenue (ttm)	788.22M
Net Income (ttm)	-206.98M
EPS (ttm)	-0.51
PE Ratio (ttm)	-7.46
Forward PE	-56.14
Analyst	Hold

Ask	3.71
Volume	54,457
Avg. Volume (20D)	104,274
Open	3.86
Previous Close	3.81
Day's Range	3.76 - 3.86
52-Week Range	2.84 - 5.64
Beta	1.67

About EVO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol EVO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for EVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Evotec SE has released their quartely earnings on Aug 13, 2025:

Revenue of $194.15M misses estimates by $44.73M, with -0.98% YoY decline.

EPS of -0.135 misses estimates by -0.01, with 53.45% YoY growth.

Next Earnings Release

Evotec SE is scheduled to release its earnings on Nov 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

-13.38%

Evotec shares are trading lower after the company ... Unlock content with Pro Subscription

4 months ago

+10.09%

Evotec shares are trading higher. The company reported FY24 financial results.

News

2 days ago · seekingalpha.com

Evotec SE (EVO) Q2 2025 Earnings Call Transcript

Evotec SE (NASDAQ:EVO ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Christian Wojczewski - CEO & Management Board Member Cord Dohrmann - Chief Scientific Officer &...

2 days ago · accessnewswire.com

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution

Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Pre...

1 week ago · accessnewswire.com

Evotec SE to announce first half-year results 2025 on 13 August 2025

HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim r...

2 weeks ago · accessnewswire.com

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site

HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-bin...

2 weeks ago · accessnewswire.com

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing cap...

3 weeks ago · benzinga.com

Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Monday.

3 weeks ago · accessnewswire.com

Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix

Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platforms High-margin technology license reven...

3 weeks ago · accessnewswire.com

Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance

HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its ...

1 month ago · accessnewswire.com

Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury

NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium ...